Acute cardiac care & resuscitation
European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization
Authors' conclusion
Substantial heterogeneity in antithrombotic practices emerged from participants' responses, potentially contributing to variable device-associated bleeding and thrombotic complications.
Study context
- Population
- European clinicians caring for adults on percutaneous mechanical circulatory support (pMCS)
- Participants
- 105 clinicians26 European countries
- Exposure
- Impella™ vs V-A ECMO
- Outcome
- Antithrombotic practices during pMCS
Methodological detailsonline survey, Survey available 17 April 2023 to 23 May 2023
- Online survey
- Survey available 17 April 2023 to 23 May 2023
Main finding
As reported in the abstract
- Adherence to locally established anticoagulation protocols
- 72.4%
- Unfractionated heparin (UFH) predominant anticoagulant, Impella™
- 97.0%
- UFH predominant anticoagulant, V-A ECMO
- 96.1%
- Anti-factor-Xa assay with aPTT for UFH monitoring, Impella™
- 10.8
- Anti-factor-Xa assay with aPTT for UFH monitoring, V-A ECMO
- 14.5%
- DAPT after ACS without percutaneous coronary intervention (PCI), Impella™
- 54.0
- DAPT after ACS without PCI, V-A ECMO
- 42.7%
- DAPT after PCI, Impella™
- 93.7
- DAPT after PCI, V-A ECMO
- 84.0%
Observational data: associations, not effects.
Original publication
European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization. Eur Heart J Acute Cardiovasc Care. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →